Cladribine Patent Expiration
Cladribine is used for treating multiple sclerosis (MS) with oral cladribine. It was first introduced by Janssen Pharmaceuticals Inc
Cladribine Patents
Given below is the list of patents protecting Cladribine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mavenclad | US12533408 | Treatment Regimen For The Treatment Of Autoimmune Disorders | Sep 10, 2041 | Emd Serono Inc |
| Mavenclad | US12539329 | Treatment Regimen For The Treatment Of Autoimmune Disorders | Sep 10, 2041 | Emd Serono Inc |
| Mavenclad | US10849919 | Cladribine regimen for treating progressive forms of multiple sclerosis | Nov 23, 2038 | Emd Serono Inc |
| Mavenclad | US7713947 | Cladribine regimen for treating multiple sclerosis | Oct 16, 2026 | Emd Serono Inc |
| Mavenclad | US8377903 | Cladribine regimen for treating multiple sclerosis |
May 31, 2026
(Expired) | Emd Serono Inc |
| Mavenclad | US7888328 | Oral formulations of cladribine |
Apr 11, 2024
(Expired) | Emd Serono Inc |
| Mavenclad | US8785415 | Oral formulations of cladribine |
Apr 11, 2024
(Expired) | Emd Serono Inc |
Cladribine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Cladribine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
